Frazier to replace Clark as prez, CEO of Merck
The board of directors at Merck has elected Kenneth C. Frazier, currently Merck’s president, as CEO and president, as well as a member of the board, effective Jan.1, 2011. Frazier will succeed Richard T. Clark, who has served as Merck’s CEO since 2005 and will continue as chairman of the board.
Since his appointment as Merck’s president in April, Frazier has focused on improving the effectiveness of its three largest divisions—pharmaceutical and vaccine sales and marketing, research and development, manufacturing and supply—as well as their post-merger integration.
As chairman, Clark will focus on leadership of the board of directors, provide strategic counsel to Frazier, oversee the planned formation of Merck's joint venture in animal health with Sanofi-Aventis and represent Merck with external organizations.
Since his appointment as Merck’s president in April, Frazier has focused on improving the effectiveness of its three largest divisions—pharmaceutical and vaccine sales and marketing, research and development, manufacturing and supply—as well as their post-merger integration.
As chairman, Clark will focus on leadership of the board of directors, provide strategic counsel to Frazier, oversee the planned formation of Merck's joint venture in animal health with Sanofi-Aventis and represent Merck with external organizations.